(HealthDay)—Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and ...
Apr 30, 2013
0
0
(HealthDay)—Anticoagulant use is associated with improved overall survival in men receiving docetaxel chemotherapy for treatment of metastatic castration-resistant prostate cancer (mCRPC), according to research presented ...
Feb 19, 2013
0
0
The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial Fibrillation, show that rivaroxaban is comparable to warfarin, which is currently the standard of care anticoagulant prescribed for ...
Nov 16, 2020
0
1
Living alone is associated with difficulties using the "blood thinner" warfarin in men, but not women, according to research presented today at ESC Congress 2019 together with the World Congress of Cardiology.
Sep 2, 2019
1
1
(HealthDay)—Among older patients undergoing hip or knee replacement, low-intensity compared with standard-intensity warfarin prophylaxis did not meet the noninferiority criterion for the composite outcome of risk of venous ...
Nov 5, 2019
0
1
As hospitals look for ways to improve patient satisfaction and boost their Medicare reimbursement, a Henry Ford Hospital study found that an inpatient pharmacist-directed anticoagulation service (PDAS) might be an unexpected ...
May 10, 2013
0
0
A new study by medical scientists coordinated from the University of Manchester has for the first time used patients' results to establish that "safety indicators" for people taking anticoagulant drugs to regulate a common ...
Jul 3, 2012
0
0
A study led by researchers at the University of North Carolina indicates that a newly approved blood thinner that blocks a key component of the human blood clotting system may increase the risk and severity of certain viral ...
Apr 1, 2013
0
0
Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not ...
Aug 18, 2015
0
6
(HealthDay)—Real-world evidence shows that rivaroxaban reduces the risk for recurrent venous thromboembolism (VTE) in morbidly obese patients, with similar safety and efficacy as warfarin, according to a study published ...
Sep 30, 2019
0
2
